NOT-NS-21-056: Notice of Early Termination of PAR-21-162, Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

Notice of Early Termination of PAR-21-162, Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

Notice Number:

NOT-NS-21-056

Key Dates

Release Date:

April 23, 2021

Related Announcements

PAR-21-162 - Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)

Issued by

National Institute of Neurological Disorders and Stroke (NINDS)

Purpose

The National Institute of Neurological Disorders and Stroke (NINDS) announces the early termination of PAR-21-162, Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional). This FOA has been reissued as PAR-21-233, "Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)." This FOA will be effective for the August 10, 2021 receipt date.

Inquiries

Please direct all inquiries to:

Ann-Marie Broome, Ph.D. MBA
National Institute of Neurological Disorders and Stroke (NINDS)
Telephone: 301-496-1779
Email: ann-marie.broome@nih.gov